Indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
See full prescribing information for complete dosing and administration instructions.
|Item #||Product Name||Supplied|
|10034057||Reconcile® 8 mg Chewable Tablets||30 ct. bottle|
|10036844||Reconcile® 8 mg Chewable Tablets||90 ct. bottle|
|10034157||Reconcile® 16 mg Chewable Tablets||30 ct. bottle|
|10036944||Reconcile® 16 mg Chewable Tablets||90 ct. bottle|
|10034257||Reconcile® 32 mg Chewable Tablets||30 ct. bottle|
|10037044||Reconcile® 32 mg Chewable Tablets||90 ct. bottle|
|10034357||Reconcile® 64 mg Chewable Tablets||30 ct. bottle|
|10037144||Reconcile® 64 mg Chewable Tablets||90 ct. bottle|
Active Ingredient(s): fluoxetine hydrochloride
IMPORTANT SAFETY INFORMATION:
The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation. Reconcile chewable tablets are contraindicated for dogs with a history of seizures or when used with MAOIs. For product label, including complete safety information, see package insert.
For oral use in dogs only. Not for human use. Keep out of reach of children.